The global urinalysis market was valued at USD 2.14 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 4.7% from 2023 to 2030. This growth is largely driven by the increasing prevalence of several key health conditions, such as Urinary Tract Infections (UTIs), diabetes, and kidney diseases, all of which necessitate frequent diagnostic testing, particularly urinalysis. The increasing awareness of kidney health and advancements in diagnostic techniques are also contributing to market expansion.
Market Drivers
One of the major drivers of the urinalysis market is the rising incidence of diseases such as UTIs, diabetes, and kidney-related disorders. For instance, according to the National Diabetes Statistics Report 2020, about 34.1 million adults aged 18 years and above in the U.S. have diabetes. Notably, one-third of individuals with diabetes suffer from kidney-related complications due to factors such as high blood sugar and high blood pressure. This makes urinalysis an invaluable diagnostic tool, as it can help detect kidney diseases early by analyzing the components of urine, which can provide vital information about kidney function.
The growing prevalence of kidney diseases, particularly in individuals with diabetes and hypertension, is expected to drive significant demand for urinalysis products. Early diagnosis of kidney conditions through urinalysis plays a crucial role in preventing further complications, such as kidney failure, making it an essential diagnostic tool for healthcare professionals.
Additionally, developing countries such as South Korea, Brazil, India, and Mexico are expected to present significant growth opportunities for the urinalysis market. These regions are witnessing an increasing burden of chronic diseases, improved healthcare infrastructure, and a rising middle class with greater access to healthcare services. In particular, countries like India are seeing an increase in healthcare spending, which grew from USD 232.73 million in 2020 to USD 507.97 million in 2021. This growing healthcare expenditure, along with a large patient base and rising disposable incomes, is expected to fuel the demand for diagnostic tools, including urinalysis products, in these markets.
Gather more insights about the market drivers, restrains and growth of the Urinalysis Market
Application Segmentation Insights
The urinary tract infection (UTI) screening segment dominated the urinalysis market in 2022, accounting for 25.06% of the market share. The high incidence of UTIs globally contributes significantly to this segment’s dominance. According to the National Center for Biotechnology Information (NCBI), approximately 150 million people worldwide suffer from UTIs each year. UTIs are one of the most common infections, especially among women and the elderly, making them a key focus for urinalysis tests. The ease and effectiveness of urinalysis in detecting UTIs help fuel the growth of this segment, which is expected to continue to be a major contributor to the overall market.
On the other hand, the diabetes screening segment is expected to grow at the fastest CAGR of 7.3% during the forecast period. Urinalysis plays a crucial role in screening for diabetes, particularly in detecting albuminuria—a condition where excess proteins, such as albumin, are present in the urine, which is a sign of kidney damage, often associated with diabetes. The steadily increasing number of people diagnosed with diabetes is a key driver for the growth of this segment. According to the Centers for Disease Control and Prevention (CDC), 37.3 million people in the U.S. were living with diabetes in 2022. Of these, 28.7 million were diagnosed, while 8.5 million remained undiagnosed. The rising number of undiagnosed cases indicates the critical need for early screening, where urinalysis can play a pivotal role in detecting early signs of the disease.
Role of Obesity in Diabetes
Obesity is a major risk factor for the development of type 2 diabetes, which is one of the primary reasons for the growing prevalence of the disease. The increasing rates of obesity, especially in developed and developing countries, are contributing to the rising number of diabetes cases. According to the International Diabetes Federation (IDF) Diabetes Atlas 2021, around 10.5% of adults aged 20 to 79 years globally have diabetes, and nearly half of them are unaware of their condition. As the global population continues to face rising obesity rates, the demand for diabetes screening through urinalysis will likely continue to grow.
The IDF projections indicate that by 2045, about 783 million adults, or 1 in 8, will be living with diabetes, marking a 46% increase from current figures. The majority of these cases will be of type 2 diabetes, which accounts for more than 90% of all diabetes cases. This type of diabetes is influenced by a range of factors, including socioeconomic status, genetics, and lifestyle factors such as diet and physical activity. The increasing global burden of diabetes will drive the demand for diagnostic tools such as urinalysis, further propelling the market for these tests.
Order a free sample PDF of the Market Intelligence Study, published by Grand View Research.
